• Genmab entered a clinical trial collaboration with Incyte and will conduct a Phase 1/2 study.
• The study will test petosemtamab with INCB161734 and chemotherapy as first-line treatment for KRAS G12D-mutated metastatic colorectal cancer.
• Incyte will co-fund the study and provide clinical supplies of INCB161734.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240700OMX_____CNEWS_EN_GNW1001279639_en) on October 24, 2026, and is solely responsible for the information contained therein.